Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.
Gut Liver. 2020 Jan 15;14(1):79-88. doi: 10.5009/gnl18471.
The survival rate of gastric cancer (GC) is known to be higher in patients with a family history (FH) of GC. There is an association between a polymorphism in the transforming growth factor-β1 () gene and the risk of GC in patients with first-degree relatives with GC. This study was performed to investigate whether a FH affects GC outcomes according to the C-509T polymorphism. was genotyped by the polymerase chain reaction-restriction fragment length polymorphism method in 1,143 GC patients, including 216 patients (18.9%) with first-degree relatives with GC. The proportion of stage I-II GCs was significantly higher in patients with a FH than in those without a FH of GC (83.8 vs 74.9%, p=0.005). The association between a FH of GC and stage I-II GC was not significant in subgroups divided based on the C-509T polymorphism and sex. A FH did not affect the overall survival rate of GC in patient with all stages and each stage. The overall survival rates were not significantly different between patients with the CC and CT/TT genotypes of the -509 polymorphism. Patient with a FH of GC had lower cancer stage (I-II) at diagnosis than those without a FH of GC, but there was no significant difference in overall survival between the patients with and without a FH of GC. A FH did not influence the tumor stage or overall survival in patients stratified by the presence of the C-509T polymorphism.
胃癌（GC）患者的生存率已知在有 GC 家族史（FH）的患者中较高。转化生长因子-β1（TGF-β1）基因中的多态性与一级亲属有 GC 的患者发生 GC 的风险之间存在关联。本研究旨在探讨 FH 是否会根据 C-509T 多态性影响 GC 的结局。在 1143 例 GC 患者中，包括 216 例（18.9%）一级亲属有 GC 的患者，通过聚合酶链反应-限制性片段长度多态性方法对 TGF-β1 进行基因分型。有 FH 的 GC 患者的 I 期- II 期 GC 比例明显高于无 FH 的 GC 患者（83.8%比 74.9%，p=0.005）。根据 C-509T 多态性和性别划分的亚组中，GC FH 与 I 期- II 期 GC 之间的关联不显著。FH 并不影响所有阶段和每个阶段 GC 患者的总生存率。-509 多态性的 CC 和 CT/TT 基因型患者的总体生存率没有显著差异。有 FH 的 GC 患者的诊断癌症分期（I-II）低于无 FH 的 GC 患者，但有 FH 和无 FH 的 GC 患者的总体生存率没有显著差异。FH 对存在 C-509T 多态性的患者的肿瘤分期或总体生存率没有影响。
